
Prothena (PRTA) Stock Forecast & Price Target
Prothena (PRTA) Analyst Ratings
Bulls say
Prothena Corp PLC has demonstrated favorable results in its clinical trials, particularly in reducing amyloid levels in patients, which is a significant milestone for its investigational therapies targeting neurodegenerative and amyloid diseases. The company has guided potential earnings of up to $105 million in aggregate milestones by 2026 from collaborations with Novo Nordisk and Bristol-Myers Squibb, highlighting the financial upside tied to its advancing pipeline. Additionally, the favorable safety profile of PRX012, despite elevated ARIA incidence, points to the potential for further development and market acceptance of Prothena's therapies.
Bears say
Prothena Corp's stock faces a negative outlook as the company is expected to continue incurring net losses until it achieves product approval and commercialization, potentially extending through the early launch phase. The need for additional capital to fund the development of its drug candidates raises concerns over potential dilution for shareholders, as the timeline and success of these candidates remain uncertain. Furthermore, evolving regulatory dynamics pose additional risks, potentially complicating pathways to approval and introducing further commercial obstacles.
This aggregate rating is based on analysts' research of Prothena and is not a guaranteed prediction by Public.com or investment advice.
Prothena (PRTA) Analyst Forecast & Price Prediction
Start investing in Prothena (PRTA)
Order type
Buy in
Order amount
Est. shares
0 shares